Six years' experience with prostaglandin I2 infusion in elective open repair of abdominal aortic aneurysm: a parallel group observational study in a tertiary referral vascular center.

Hdl Handle:
http://hdl.handle.net/10147/304780
Title:
Six years' experience with prostaglandin I2 infusion in elective open repair of abdominal aortic aneurysm: a parallel group observational study in a tertiary referral vascular center.
Authors:
Beirne, Chris; Hynes, Niamh; Sultan, Sherif
Affiliation:
Department of Vascular and Endovascular Surgery, Western Vascular Institute, Galway University Hospitals, Galway, Ireland.
Citation:
Six years' experience with prostaglandin I2 infusion in elective open repair of abdominal aortic aneurysm: a parallel group observational study in a tertiary referral vascular center. 2008, 22 (6):750-5 Ann Vasc Surg
Publisher:
Annals of vascular surgery
Journal:
Annals of vascular surgery
Issue Date:
Nov-2008
URI:
http://hdl.handle.net/10147/304780
DOI:
10.1016/j.avsg.2008.08.036
PubMed ID:
18992665
Abstract:
The prostaglandin I(2) (PGI(2)) analogue iloprost, a potent vasodilator and inhibitor of platelet activation, has traditionally been utilized in pulmonary hypertension and off-label use for revascularization of chronic critical lower limb ischemia. This study was designed to assess the effect of 72 hr iloprost infusion on systemic ischemia post-open elective abdominal aortic aneurysm (EAAA) surgery. Between January 2000 and 2007, 104 patients undergoing open EAAA were identified: 36 had juxtarenal, 15 had suprarenal, and 53 had infrarenal aneurysms, with a mean maximal diameter of 6.9 cm. The male-to-female ratio was 2.5:1, with a mean age of 71.9 years. No statistically significant difference was seen between the study groups with regard to age, sex, risk factors, American Society of Anesthesiologists (ASA) grade, or diameter of aneurysm repaired. All emergency, urgent, and endovascular procedures for aneurysms were excluded. Fifty-seven patients received iloprost infusion for 72 hr in the immediate postoperative period compared with 47 patients who did not. Patients were monitored for signs of pulmonary, renal, cardiac, systemic ischemia, and postoperative intensive care unit (ICU) morbidity. Statistically significantly increased ventilation rates (p=0.0048), pulmonary complication rates (p=0.0019), and myocardial ischemia (p=0.0446) were noted in those patients not receiving iloprost. These patients also had significantly higher renal indices including estimate glomerular filtration rate changes (p=0.041) and postoperative urea level rises (p=0.0286). Peripheral limb trashing was noted in five patients (11.6%) in the non-iloprost group compared with no patients who received iloprost. Increased rates of transfusion requirements and bowel complications were noted in those who did not receive iloprost, with their ICU stay greater than twice that of iloprost patients. All-cause morbidity affected 67% of patients not receiving iloprost compared to 40% who did. Survival rates were significantly better with iloprost than without in both 30-day (p=0.009) and 5-year cumulative (p=0.0187) survival. Iloprost infusion for 72 hr after open AAA repair was associated with improved systemic perfusion and decreased systemic ischemia. Patients had a significant survival benefit at 30 days and 5 years and significantly improved renal, cardiac, and respiratory function.
Item Type:
Article
Language:
en
MeSH:
Aged; Aortic Aneurysm, Abdominal; Databases as Topic; Epoprostenol; Female; Gastrointestinal Diseases; Glomerular Filtration Rate; Humans; Infusions, Parenteral; Intensive Care; Ischemia; Kidney; Lung; Male; Myocardial Ischemia; Platelet Aggregation Inhibitors; Regional Blood Flow; Respiration, Artificial; Surgical Procedures, Elective; Time Factors; Treatment Outcome; Vascular Surgical Procedures; Vasodilator Agents
ISSN:
1615-5947

Full metadata record

DC FieldValue Language
dc.contributor.authorBeirne, Chrisen_GB
dc.contributor.authorHynes, Niamhen_GB
dc.contributor.authorSultan, Sherifen_GB
dc.date.accessioned2013-10-30T14:21:51Z-
dc.date.available2013-10-30T14:21:51Z-
dc.date.issued2008-11-
dc.identifier.citationSix years' experience with prostaglandin I2 infusion in elective open repair of abdominal aortic aneurysm: a parallel group observational study in a tertiary referral vascular center. 2008, 22 (6):750-5 Ann Vasc Surgen_GB
dc.identifier.issn1615-5947-
dc.identifier.pmid18992665-
dc.identifier.doi10.1016/j.avsg.2008.08.036-
dc.identifier.urihttp://hdl.handle.net/10147/304780-
dc.description.abstractThe prostaglandin I(2) (PGI(2)) analogue iloprost, a potent vasodilator and inhibitor of platelet activation, has traditionally been utilized in pulmonary hypertension and off-label use for revascularization of chronic critical lower limb ischemia. This study was designed to assess the effect of 72 hr iloprost infusion on systemic ischemia post-open elective abdominal aortic aneurysm (EAAA) surgery. Between January 2000 and 2007, 104 patients undergoing open EAAA were identified: 36 had juxtarenal, 15 had suprarenal, and 53 had infrarenal aneurysms, with a mean maximal diameter of 6.9 cm. The male-to-female ratio was 2.5:1, with a mean age of 71.9 years. No statistically significant difference was seen between the study groups with regard to age, sex, risk factors, American Society of Anesthesiologists (ASA) grade, or diameter of aneurysm repaired. All emergency, urgent, and endovascular procedures for aneurysms were excluded. Fifty-seven patients received iloprost infusion for 72 hr in the immediate postoperative period compared with 47 patients who did not. Patients were monitored for signs of pulmonary, renal, cardiac, systemic ischemia, and postoperative intensive care unit (ICU) morbidity. Statistically significantly increased ventilation rates (p=0.0048), pulmonary complication rates (p=0.0019), and myocardial ischemia (p=0.0446) were noted in those patients not receiving iloprost. These patients also had significantly higher renal indices including estimate glomerular filtration rate changes (p=0.041) and postoperative urea level rises (p=0.0286). Peripheral limb trashing was noted in five patients (11.6%) in the non-iloprost group compared with no patients who received iloprost. Increased rates of transfusion requirements and bowel complications were noted in those who did not receive iloprost, with their ICU stay greater than twice that of iloprost patients. All-cause morbidity affected 67% of patients not receiving iloprost compared to 40% who did. Survival rates were significantly better with iloprost than without in both 30-day (p=0.009) and 5-year cumulative (p=0.0187) survival. Iloprost infusion for 72 hr after open AAA repair was associated with improved systemic perfusion and decreased systemic ischemia. Patients had a significant survival benefit at 30 days and 5 years and significantly improved renal, cardiac, and respiratory function.en_GB
dc.language.isoenen
dc.publisherAnnals of vascular surgeryen_GB
dc.rightsArchived with thanks to Annals of vascular surgeryen_GB
dc.subject.meshAged-
dc.subject.meshAortic Aneurysm, Abdominal-
dc.subject.meshDatabases as Topic-
dc.subject.meshEpoprostenol-
dc.subject.meshFemale-
dc.subject.meshGastrointestinal Diseases-
dc.subject.meshGlomerular Filtration Rate-
dc.subject.meshHumans-
dc.subject.meshInfusions, Parenteral-
dc.subject.meshIntensive Care-
dc.subject.meshIschemia-
dc.subject.meshKidney-
dc.subject.meshLung-
dc.subject.meshMale-
dc.subject.meshMyocardial Ischemia-
dc.subject.meshPlatelet Aggregation Inhibitors-
dc.subject.meshRegional Blood Flow-
dc.subject.meshRespiration, Artificial-
dc.subject.meshSurgical Procedures, Elective-
dc.subject.meshTime Factors-
dc.subject.meshTreatment Outcome-
dc.subject.meshVascular Surgical Procedures-
dc.subject.meshVasodilator Agents-
dc.titleSix years' experience with prostaglandin I2 infusion in elective open repair of abdominal aortic aneurysm: a parallel group observational study in a tertiary referral vascular center.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Vascular and Endovascular Surgery, Western Vascular Institute, Galway University Hospitals, Galway, Ireland.en_GB
dc.identifier.journalAnnals of vascular surgeryen_GB
dc.description.fundingNo fundingen
dc.description.provinceConnachten
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.